Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-004870-22
    Sponsor's Protocol Code Number:AMB-051-02
    National Competent Authority:Netherlands - Competent Authority
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-05-11
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNetherlands - Competent Authority
    A.2EudraCT number2020-004870-22
    A.3Full title of the trial
    A Phase 2, Adaptive, Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Intravenous AMB-05X in Subjects with Tenosynovial Giant Cell Tumor
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study to evaluate treatment with intravenous AMB-05X in subjects with Tenosynovial Giant Cell Tumor
    A.4.1Sponsor's protocol code numberAMB-051-02
    A.5.4Other Identifiers
    Name:US IND NUMBERNumber:100835
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAmMax Bio., Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAmMax Bio., Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAmMax Bio., Inc.
    B.5.2Functional name of contact pointSenior Director, Clinical Operation
    B.5.3 Address:
    B.5.3.1Street Address555 Twin Dolphin Drive, Suite 610
    B.5.3.2Town/ cityRedwood City, CA
    B.5.3.3Post code94065
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1(650) 492-9484
    B.5.5Fax number+1(650) 285-6564
    B.5.6E-mailtiffanynguyen@ammaxbio.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAMB-05X
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNnot yet assigned
    D.3.9.1CAS number not assigned
    D.3.9.2Current sponsor codeAMB-05X
    D.3.9.3Other descriptive nameAMG 820
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number70
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Tenosynovial Giant Cell Tumor
    E.1.1.1Medical condition in easily understood language
    Tenosynovial Giant Cell Tumor
    E.1.1.2Therapeutic area Diseases [C] - Musculoskeletal Diseases [C05]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10018253
    E.1.2Term Giant cell tumor of tendon sheath
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    to evaluate the safety, efficacy, and PK of AMB-05X in the treatment of TGCT
    E.2.2Secondary objectives of the trial
    not applicable
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male or female ≥18 years of age.
    2. Able to communicate well with study staff, understand and comply with
    the requirements of the study, and read and voluntarily sign the informed
    consent form (ICF) and the Health Insurance Portability and
    Accountability Act (HIPAA) authorization (if applicable) before the
    conduct of any study-specific procedures.
    3. TGCT that meets both of the following criteria:
    a. Diagnosis has been histologically confirmed by a pathologist. If the
    diagnosis has not been previously histologically confirmed, biopsy
    with histological confirmation is required before enrollment.
    b. Has not been surgically resected either because surgical resection
    would be associated with potentially worsening functional limitation
    / severe morbidity (locally advanced disease) or because the subject
    declined surgery.
    4. Measurable disease as defined by RECIST v1.1 (except with a minimum
    size of 2 cm), assessed from MRI scans by a central radiologist.
    5. Symptomatic disease defined as one or both of the following:
    a. A score of at least 4 on the Worst Pain NRS at Screening.
    b. A score of at least 4 on the Worst Stiffness NRS at Screening.
    6. Stable prescription of analgesic regimen during the 2 weeks before
    Baseline.
    7. Women of childbearing potential must have a negative serum pregnancy
    test at Screening and a negative urine pregnancy test at Baseline.
    8. Agrees to follow contraception guidelines (see Section 5.3).
    9. Adequate hematologic, hepatic, and renal function at Screening, defined
    by:
    • Absolute neutrophil count ≥ 1.5 × 109/L
    • Aspartate aminotransferase (AST) and alanine aminotransferase
    (ALT) ≤ 1.5 × upper limit of normal (ULN)
    • Hemoglobin > 10 g/dL
    • Total bilirubin ≤ 1.5 × ULN
    • Platelet count ≥ 100 × 109/L
    • Serum creatinine ≤ 1.5 × ULN
    10. Willing and able to complete the PROMIS Physical Function Scale,
    Worst Stiffness NRS, BPI, and EQ-5D-5L throughout the study.
    E.4Principal exclusion criteria
    1. Use of any investigational drug within 4 weeks or 5 half-lives (whichever
    is longer) before Baseline.
    2. Any previous use of pexidartinib or any biologic treatment targeting
    CSF1 or CSF1R. Use of an oral tyrosine kinase inhibitor other than
    pexidartinib (eg, imatinib or nilotinib) within 3 months before Baseline.
    3. Active cancer (either currently or within 1 year before Baseline) that
    requires/required therapy (eg, surgery, chemotherapy, or radiation
    therapy), with the exception of adequately treated basal or squamous cell
    carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix
    or breast, or prostate carcinoma not requiring treatment apart from active
    surveillance.
    4. Known metastatic TGCT.
    5. Hepatitis C virus (HCV) or hepatitis B virus (HBV) or known active or
    chronic infection with human immunodeficiency virus (HIV).
    6. Known active tuberculosis (TB).
    7. Significant concomitant arthropathy in the affected joint, serious illness,
    uncontrolled infection, or a medical or psychiatric history that, in the
    Investigator's opinion, would likely interfere with the subject’s study
    participation or the interpretation of the subject’s results.
    8. A woman who is breastfeeding.
    9. A screening Fridericia-corrected QT interval (QTcF) ≥450 ms (men) or
    ≥470 ms (women)
    10. MRI contraindications (eg, pacemaker, loose metallic implants)
    11. History of hypersensitivity to any ingredient in the study drug.
    12. History of drug or alcohol abuse within 3 months before Baseline.
    13. Has any other severe acute or chronic medical or psychiatric condition or
    clinically significant laboratory abnormality that may increase the risk
    associated with study participation/treatment, interfere with interpretation
    of study results, or, in the Investigator’s opinion, make the subject
    inappropriate for this study.
    14. A subject who, in the opinion of the Investigator, should not participate
    in this study for any reason, including instances where the subject’s
    stability or ability to comply with study requirements is in question.
    E.5 End points
    E.5.1Primary end point(s)
    Frequency and severity of reported treatment-emergent adverse events
    (TEAEs)
    E.5.1.1Timepoint(s) of evaluation of this end point
    at Week 12
    E.5.2Secondary end point(s)
    The following efficacy endpoints will be assessed at Week 12:

    • The proportion of subjects who achieve an overall tumor response (objective
    response [OR], which includes both complete response [CR] and partial
    response [PR]) per the Response Evaluation Criteria in Solid Tumors Version
    1.1 (RECIST v1.1)
    • Proportion of subjects with overall response based on tumor volume
    score (TVS), a TGCT-specific method that calculates tumor volume as a
    percentage of the estimated maximally distended synovial cavity
    • Mean change from Baseline in range of motion (ROM) score
    • Mean change from Baseline in the Patient-Reported Outcomes
    Measurement Information System (PROMIS) Physical Function score
    • Mean change from Baseline in Worst Stiffness Numeric Rating Scale
    (NRS) score
    • Percentage of subjects who respond with a decrease of at least 30% in
    mean Brief Pain Inventory (BPI) score from Baseline
    • Mean change from Baseline in BPI score
    • Mean change from Baseline in Worst Pain NRS score
    • Mean change from Baseline in EQ-5D-5L health assessment

    Pharmacokinetics and Pharmacodynamics
    • Serum (and optional synovial) AMB-05X levels
    • Serum (and optional synovial) AMB-05X–binding anti-drug antibody
    (ADA) levels
    • Serum (and optional synovial) colony-stimulating factor 1 (CSF1) levels
    E.5.2.1Timepoint(s) of evaluation of this end point
    DMC will begin to review study data after the first 3 subjects complete Week 6 and continue to review data throughout the study (each time at least 3 additional subjects [from any cohort] complete Week 12)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Dose-Escalation
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA7
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Ukraine
    United States
    Germany
    Hungary
    Netherlands
    Poland
    Czechia
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months9
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 27
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 9
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 28
    F.4.2.2In the whole clinical trial 36
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Standard treatment
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-05-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-09-02
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2022-04-20
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 04 16:16:05 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA